UConn John Dempsey Hospital Performs Connecticut’s First Valve Implant for Emphysema

UConn John Dempsey Hospital is first in Connecticut to offer severe emphysema patients an innovative, minimally invasive valve implant to help them breathe easier.

On August 10 UConn Health’s Dr. Omar Ibrahim, director of interventional pulmonary medicine in the Department of Medicine, performed the state’s first procedure using the FDA-approved Zephyr Valve.

The tiny valve devices allow severe emphysema patients to breathe better, be more active and have improved quality of life by improving their lung function. According to Ibrahim the technology will also help his patients improve their results of pulmonary lung function tests, decrease their shortness of breath, and reduce their daily reliance on supplemental oxygen.

“This procedure is giving severe emphysema patients a new lease on life by making it easier for them to breathe again by blocking off the most diseased section of their lung and allowing the healthy parts of the lung to function better,” says Ibrahim. “This technology is going to help improve not only my emphysema patients’ breathing but their quality of life by lifting the current restrictions on their daily activities. They will now be able to enjoy life again, play with their grandkids, and go on walks.”

Ibrahim adds: “This technology is a true game-changer for patients with severe emphysema. It’s a new solution we can offer the citizens of our state living each day with very difficult and debilitating emphysema. The disease has not had a significant treatment breakthrough in a very long time.”

Connecticut’s First Emphysema Valve Patient

“I feel good,” shared Stephen Petty, 73 of Colchester. He is the first patient in Connecticut to receive a novel valve implant to improve his emphysema breathing difficulties.

Petty was originally scheduled for the innovative minimally invasive Zephyr Valve procedure in mid-March but COVID-19 hit the state and he’s been waiting ever since for the big day that finally arrived on August 10.
“To be the first patient at UConn is great,” Petty shared happily. “Dr. Ibrahim has been absolutely phenomenal along with the staff. Everyone’s been fantastic.”

He first started to experience some shortness of breath during his thirties and began seeing a pulmonologist. But the shortness of breath continued to worsen over the years.

“I was getting worse and worse,” says Petty. “Every time I walked outside I would have to take a shot of my inhaler.”

Finally at the age of 59 Petty, who was a past smoker, was diagnosed with the genetic condition Alpha-1 antitrypsin deficiency which can lead to lung disease including the development of emphysema.

“I am very happy,” says Petty. “I am looking forward to operating daily without having oxygen strung around me and feeling better.”

Also, he looks forward to getting back to doing what he loves doing – riding a bicycle.

“That’s what I want to get back into,” shared Petty and his UConn Health team has the same hope.

“He wants to get back to riding his bike and we are determined to get him to his goal,” says his surgeon Dr. Omar Ibrahim.

Emphysema is the severest form of chronic obstructive pulmonary disease (COPD). The disease causes patients to feel short of breath, and breathless or unable to take a deep breath at times. It is most often caused by smoking or a history of smoking, but it also can be caused by a genetic condition.

Patients with emphysema can experience a hyperinflation of their lungs. This is air trapped inside lung lobes with no way for the air to escape causing the lungs to become enlarged. As a result, a patient’s chest is over expanded causing an imbalance in inhalation and exhalation of air. The condition can be life-threatening.

*The new Zephyr Valves are minimally invasively implanted into a patient’s lung airways to improve lung function and breathing (Image by Pulmonx Corp.).*

The tiny Zephyr Valves are minimally invasively implanted into a patient’s lung lobes airways using a bronchoscope with a flexible catheter; no cutting or incision is required. The device is deployed to block the airways to allow air to flow out of the lung lobes but not back in so the lobes have a chance to properly deflate and begin to function normally allowing the patient to more easily breathe in and out. Each patient receives about four valves on average during a procedure.

“Severe emphysema patients and pulmonary doctors from across the state now have a trusted place here at UConn Health to turn to for this new minimally invasive solution, with proper protocols and facilities,” says Ibrahim. “We are already partnering with other local hospitals and other facilities to help get patients the latest available care option they may need.”

Candidates for the new valve procedure are patients with severe emphysema who have exhausted all other traditional medical therapies. This patient population is high-risk for having a traditional lung volume reduction surgery option due to risk of complications and morbidity.

Recent Articles

School of Pharmacy’s Megan Delaney Receives 2024 Provost Award

In Memoriam: UConn Law Professor Joseph Harbaugh

Historian Manisha Sinha Awarded Southern Historical Association Honor